Delenex Therapeutics AG

Delenex Therapeutics AG: Extension of Scientific Advisory Board

Delenex Therapeutics AG: In Vitro and in Vivo Efficacy of DLX1008 in Human Glioma Models

Delenex Therapeutics AG: Anti-Tumor Activity of DLX1008 in an In Vivo Model of Kaposi Sarcoma

Delenex Therapeutics AG: New Clinical Data Show Biological Activity of DLX105 in Patients with Behçet’s Disease

Delenex Therapeutics AG Expands Pipeline

Delenex Therapeutics AG: New Clinical Data Show Biologic Activity of DLX105 upon Topical Application onto Psoriatic Skin

Delenex Therapeutics AG: New Clinical Data on the Topical Application of PENTRA(R)Bodies to be Presented at the 44th Annual ESDR Meeting

Delenex Therapeutics AG Establishes Avisory Board

Jens Henneke joins Delenex Therapeutics AG as Business and Corporate Development Advisor

Delenex Therapeutics AG closes CHF 7.3 (USD 8.0) million Series A3 Financing